ArticleAnti-cancer agents in medicinal chemistry2026
Investigation of the Immunomodulatory Effect of Quinoline Derivatives with Antitumor Activity.
Article in Anti-cancer agents in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn the last two decades, quinoline derivatives have garnered significant attention for their anticancer and immunomodulatory properties. These compounds have shown potential in modulating inflammatory responses, which are often implicated in cancer progression. This study aimed to evaluate the immunomodulatory effects and anti-migratory properties of three novel quinoline derivatives in THP-1-derived macrophage-like cells.
methodsMacrophage-like cells derived from the THP-1 cell line were treated with three quinoline derivatives (3c, 3d, and 3e). The expression levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and the antiinflammatory cytokine IL-10 were measured. Additionally, the compounds' effects on the expression of migration- related genes and their ability to inhibit cell migration were assessed.
resultsTreatment with quinoline derivatives led to a significant reduction in TNF-α, IL-1α, and IL-6 expression, particularly with compounds 3c and 3d. In contrast, compound 3e induced a weaker response in proinflammatory cytokine suppression but notably elevated IL-10 levels. Furthermore, all three compounds demonstrated concentration-dependent inhibition of cell migration, with compound 3c showing the most substantial effect and pronounced changes in migration-related gene expression. DISCUSSION: The tested quinoline derivatives exhibit promising immunomodulatory and anti-migratory activities. Compound 3c, in particular, emerged as a strong candidate for further investigation due to its robust antiinflammatory and migration-inhibitory effects.
conclusionThese findings highlight the therapeutic potential of quinoline derivatives in managing inflammation- associated cancer progression.
Indexed as
Identifiers
41755408What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.